Data Debate: Paclitaxel Device Meeting Shows Rift in Regard for Real-World Evidence

article image

Real-world, observational data sources are attracting massive interest in the medical device space as tools to support regulatory decisions and more. But there certainly is not full consensus about what they are good for, as was laid bare at a recent FDA advisory panel meeting investigating safety data for peripheral artery disease devices.

Are real-world data from registries, insurance claims and the like the device sector’s savior from imperfect and expensive randomized controlled trial practices, or are they full of empty promises?

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: